ZIOPHARM Oncology, Inc. – NASDAQ:ZIOP

Add to watchlist

$0.866

+0.86

Market closed

Open in 3 days

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	208.12M
Enterprise value	123.63M

P/E	-2.06
EV/Sales	310.63
EV/EBITDA	-1.41
Price/Sales	466.65
Price/Book	2.70
PEG ratio	-0.04
EPS	-0.43

Revenue	N/A
EBITDA	-87.41M
Income	-89.72M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-22544.97%
Oper. margin	-22430.15%
Gross margin	0%
EBIT margin	-22430.15%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Profit margin
Dec 2020	0	-22.77M
Mar 2021	0	-21.55M
Jun 2021	0	-22.67M
Sep 2021	398K	-22.73M	-5711.81%

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Earnings per share (EPS)
2021-05-06	-0.1	-0.1
2021-08-13	-0.14	-0.11
2021-11-08	-0.13	-0.11

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Debt to assets
Dec 2020	146345000	22.36M	15.28%
Mar 2021	128472000	22.83M	17.77%
Jun 2021	106765000	18.48M	17.31%
Sep 2021	113762000	45.05M	39.6%

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Cash Flow
Dec 2020	-17.03M	-3.76M	400K
Mar 2021	-15.31M	-717K	1.01M
Jun 2021	-21.45M	-1.87M	19K
Sep 2021	-9.57M	-370K	24.92M

ZIOPHARM Oncology alternative data

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Employee count
Aug 2023	103
Sep 2023	103
Oct 2023	103
Nov 2023	103
Dec 2023	103
Jan 2024	103
Feb 2024	103
Mar 2024	103
Apr 2024	103
May 2024	103
Jun 2024	103
Jul 2024	103

ZIOPHARM Oncology
Insider Trading

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Insider trades (number of shares)
Period	Buy	Sel
Jan 2021	0	199727
Sep 2021	423770	0
Nov 2021	10000	0
Dec 2021	0	20132

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	22 Dec 2021	DE GROOT ELEANOR officer: EVP, Ope..	Common Stock	20,132	$1.27	$25,568
Purchase	17 Nov 2021	BOYLE KEVIN S. SR. director, officer: Chief Executive Offi.. director, officer: Chief Execut..	Common Stock	9,116	$1.4	$12,762
Purchase	16 Nov 2021	BOYLE KEVIN S. SR. director, officer: Chief Executive Offi.. director, officer: Chief Execut..	Common Stock	884	$1.4	$1,238
Purchase	29 Sep 2021	VIESER JAIME director director	Common Stock	100,000	$1.91	$191,000
Purchase	2 Sep 2021	POSTMA ROBERT W	Common Stock	75,000	$1.73	$129,750
Purchase	2 Sep 2021	HAGEN HEIDI director director	Common Stock	23,770	$1.76	$41,835
Purchase	2 Sep 2021	POSTMA ROBERT W director director	Common Stock	75,000	$1.73	$129,750
Purchase	1 Sep 2021	HUANG JAMES director director	Common Stock	100,000	$1.71	$171,000
Purchase	1 Sep 2021	WEIS HOLGER	Common Stock	50,000	$1.83	$91,500
Sale	8 Jan 2021	BUCK JILL officer: EVP, GM Gene Therapy officer: EVP, GM Gene Therapy	Common Stock	27,894	$3.12	$87,029

ZIOP insider trading transactions

ZIOPHARM Oncology
Earnings Call Transcripts

Quarter	Transcript
Q3 2021 8 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 9 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 6 May 2021	Q1 2021 Earnings Call Transcript
Q4 2020 25 Feb 2021	Q4 2020 Earnings Call Transcript

ZIOP earnings call transcripts

ZIOPHARM Oncology
Executives

Insider	Age	Compensation
Dr. Eleanor de Groot Ph.D. (1969) Executive Vice President of Operations	56	$488,980
Dr. Raffaele Baffa M.D., Ph.D. (1961) Chief Medical Officer and Executive Vice President of R&D	64	$242,830
Mr. Zuie-Chin Huang M.B.A. (1966) Executive Chairman	59	$22,280

ZIOPHARM Oncology
Latest News

Wednesday, 19 January 2022
17:35	Why Ziopharm Oncology Shares Rose 10.5% on Wednesday	The Motley Fool
Tuesday, 23 November 2021
06:58	ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?	Zacks Investment Research
Monday, 8 November 2021
19:45	ZIOPHARM Oncology, Inc. (ZIOP) CEO Kevin Boyle on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 1 November 2021
16:30	Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021	GlobeNewsWire
Wednesday, 6 October 2021
07:48	Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch	PennyStocks
Tuesday, 28 September 2021
05:53	ZIOP Stock: Why It Decreased Today	Pulse2
Monday, 27 September 2021
16:05	Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway	GlobeNewsWire
Friday, 10 September 2021
09:00	Here's Why Ziopharm Oncology Stock Is Up 18% This Week	The Motley Fool
Wednesday, 8 September 2021
10:14	Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?	Zacks Investment Research
Tuesday, 7 September 2021
12:12	ZIOP Stock: Over 45% Increase Explanation	Pulse2
Wednesday, 1 September 2021
16:36	Why Shares of Ziopharm Oncology Jumped on Wednesday	The Motley Fool
16:05	Ziopharm Oncology to Participate in September Investor Conferences	GlobeNewsWire
Monday, 30 August 2021
08:30	Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 6 Sep 2021

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Frequently Asked Questions (FAQ)

What's the price of ZIOPHARM Oncology stock today?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $0.87.
When is ZIOPHARM Oncology's next earnings date?

Unfortunately, ZIOPHARM Oncology's (ZIOP) next earnings date is currently unknown.
Does ZIOPHARM Oncology pay dividends?

No, ZIOPHARM Oncology does not pay dividends.
How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of 208.12M. ZIOPHARM Oncology made a loss 79.98M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology, Inc. is traded on the NASDAQ under the ticker symbol "ZIOP".
What is ZIOPHARM Oncology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of ZIOPHARM Oncology?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the following people:
- Dr. Eleanor de Groot Ph.D. Executive Vice President of Operations(age: 56, pay: $488,980)
- Dr. Raffaele Baffa M.D., Ph.D. Chief Medical Officer and Executive Vice President of R&D(age: 64, pay: $242,830)
- Mr. Zuie-Chin Huang M.B.A. Executive Chairman(age: 59, pay: $22,280)
How many employees does ZIOPHARM Oncology have?

As Jul 2024, ZIOPHARM Oncology employs 103 workers.
When ZIOPHARM Oncology went public?

ZIOPHARM Oncology, Inc. is publicly traded company for more then 21 years since IPO on 20 Aug 2004.
What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is ziopharm.com.
Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at One First Avenue Parris Building 34, Navy Yard Plaza, Boston, MASSACHUSETTS.
How can i contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is One First Avenue Parris Building 34, Navy Yard Plaza, Boston, MASSACHUSETTS and company can be reached via phone at +1 617 259 1970.

ZIOPHARM Oncology, Inc.

ziopharm.com

Exchange:

NASDAQ

Full time employees:

103

Industry:

Biotechnology

Sector:

Healthcare

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

+1 617 259 1970

One First Avenue Parris Building 34, Navy Yard Plaza
Boston, MASSACHUSETTS 02129

CIK: 0001107421
ISIN: US98973P1012
CUSIP: 98973P101